Overall rank by patents
#45,731
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Candesant Biomedical, Inc.
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2020–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
5
Total patents granted
3
CPC technology areas
26.0
Avg claims per patent
-
5-year filing velocity
The verdict
Candesant holds 5 US patents across 3 technology areas, rank #45,731 of 50,000 tracked assignees.
- #45,731
- of 50,000 US assignees by volume
- Top 44%
- by Innovation Score (37.3/100)
- 26.0
- avg claims per patent
Portfolio overview
Candesant Biomedical, Inc. has been granted 5 US utility patents between 2020 and 2024, placing Candesant Biomedical, Inc. at rank #45,731 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.0 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Candesant Biomedical, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Candesant sits between Cansemi Technology Inc. (5 patents, rank #45,727) and Capital Safety Group (northern Europe) Limited (5 patents, rank #45,735) - the closest US assignees by grant volume. The composite Innovation Score of 37.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2024, with 5 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Candesant Biomedical, Inc.'s 26.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Candesant Biomedical, Inc. against peers pursuing similar technology classes.
Who files at Candesant's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cansemi Technology
CanSemi Technology Inc.
5 patents
- Canwell Biotech
CanWell Biotech Limited
5 patents
- Canada Goose
Canada Goose Inc.
5 patents
- Cancer Prevention…
Cancer Prevention Pharmaceuticals, Inc.
5 patents
- Cane Creek Cyclin…
Cane Creek Cycling Components, Inc.
5 patents
- Cangrade
Cangrade, Inc.
5 patents
- Canna-chemistries
Canna-Chemistries LLC
5 patents
- Capital Safety Gr…
Capital Safety Group (Northern Europe) Limited
5 patents
- Candesant Biomedi… ◀
Candesant Biomedical, Inc.
5 patents
What this shows Candesant holds 5 patents at rank #45,731, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Candesant
By rank, the assignees closest to #45,731 in granted patent volume.
- Cansemi Technology Inc. #45,727 · 5 patents
- Canwell Biotech Limited #45,728 · 5 patents
- Canada Goose Inc. #45,729 · 5 patents
- Cancer Prevention Pharmaceuticals, Inc. #45,730 · 5 patents
- Cane Creek Cycling Components, Inc. #45,732 · 5 patents
- Cangrade, Inc. #45,733 · 5 patents
- Canna-chemistries Llc #45,734 · 5 patents
- Capital Safety Group (northern Europe) Limited #45,735 · 5 patents
Leaders in A61F (Filters Implantable INTO Blood Vessels)
Other assignees with the most granted patents in Candesant's primary technology class.
- The Procter & Gamble Company 1,426 in class
- Boston Scientific Scimed, Inc. 1,101 in class
- Edwards Lifesciences Corporation 1,101 in class
- Depuy Synthes Products, Inc. 851 in class
- Globus Medical, Inc. 752 in class
- COOK Medical Technologies Llc 700 in class
- Smith & Nephew, Inc. 541 in class
- Covidien Lp 528 in class
Candesant's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
37 Top 44% higher than 56% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 20.0% |
| 2021 | 1 | 20.0% |
| 2023 | 1 | 20.0% |
| 2024 | 2 | 40.0% |
Which technologies does Candesant Biomedical, Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Frequently Asked Questions
How many patents does Candesant Biomedical, Inc. hold?
Candesant Biomedical, Inc. holds 5 US granted patents filed between 2020 and 2024, spanning 3 technology areas.
What is Candesant Biomedical, Inc.'s Innovation Score?
Candesant Biomedical, Inc. has an Innovation Score of 37.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Candesant Biomedical, Inc. focus on?
Candesant Biomedical, Inc.'s top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 5 patents. The company has filed patents in 3 CPC subclasses total.
Is Candesant Biomedical, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Candesant Biomedical, Inc..
What does claim depth mean for Candesant Biomedical, Inc.'s patents?
Candesant Biomedical, Inc.'s patents average 26.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Candesant Biomedical, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Candesant's 5 grants land it in the top 44% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Candesant ranks #45,731 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61F - see who else leads that technology area. A61F leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.